Literature DB >> 21820096

Recessive mutations in DOCK6, encoding the guanidine nucleotide exchange factor DOCK6, lead to abnormal actin cytoskeleton organization and Adams-Oliver syndrome.

Ranad Shaheen1, Eissa Faqeih, Asma Sunker, Heba Morsy, Tarfa Al-Sheddi, Hanan E Shamseldin, Nouran Adly, Mais Hashem, Fowzan S Alkuraya.   

Abstract

Adams-Oliver syndrome (AOS) is defined by the combination of aplasia cutis congenita (ACC) and terminal transverse limb defects (TTLD). It is usually inherited as an autosomal-dominant trait, but autosomal-recessive inheritance has also been documented. In an individual with autosomal-recessive AOS, we combined autozygome analysis with exome sequencing to identify a homozygous truncating mutation in dedicator of cytokinesis 6 gene (DOCK6) which encodes an atypical guanidine exchange factor (GEF) known to activate two members of the Rho GTPase family: Cdc42 and Rac1. Another homozygous truncating mutation was identified upon targeted sequencing of DOCK6 in an unrelated individual with AOS. Consistent with the established role of Cdc42 and Rac1 in the organization of the actin cytoskeleton, we demonstrate a cellular phenotype typical of a defective actin cytoskeleton in patient cells. These findings, combined with a Dock6 expression profile that is consistent with an AOS phenotype as well as the very recent demonstration of dominant mutations of ARHGAP31 in AOS, establish Cdc42 and Rac1 as key molecules in the pathogenesis of AOS and suggest that other regulators of these Rho GTPase proteins might be good candidates in the quest to define the genetic spectrum of this genetically heterogeneous condition.
Copyright © 2011 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21820096      PMCID: PMC3155174          DOI: 10.1016/j.ajhg.2011.07.009

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  36 in total

1.  Identification of an evolutionarily conserved superfamily of DOCK180-related proteins with guanine nucleotide exchange activity.

Authors:  Jean-François Côté; Kristiina Vuori
Journal:  J Cell Sci       Date:  2002-12-15       Impact factor: 5.285

2.  Unconventional Rac-GEF activity is mediated through the Dock180-ELMO complex.

Authors:  Enrico Brugnera; Lisa Haney; Cynthia Grimsley; Mingjian Lu; Scott F Walk; Annie-Carole Tosello-Trampont; Ian G Macara; Hiten Madhani; Gerald R Fink; Kodimangalam S Ravichandran
Journal:  Nat Cell Biol       Date:  2002-08       Impact factor: 28.824

Review 3.  Cellular signaling of Dock family proteins in neural function.

Authors:  Yuki Miyamoto; Junji Yamauchi
Journal:  Cell Signal       Date:  2009-09-30       Impact factor: 4.315

Review 4.  Budding behaviors: Growth of the limb as a model of morphogenesis.

Authors:  Sevan Hopyan; James Sharpe; Yingzi Yang
Journal:  Dev Dyn       Date:  2011-03-07       Impact factor: 3.780

5.  Gain-of-function mutations of ARHGAP31, a Cdc42/Rac1 GTPase regulator, cause syndromic cutis aplasia and limb anomalies.

Authors:  Laura Southgate; Rajiv D Machado; Katie M Snape; Martin Primeau; Dimitra Dafou; Deborah M Ruddy; Peter A Branney; Malcolm Fisher; Grace J Lee; Michael A Simpson; Yi He; Teisha Y Bradshaw; Bettina Blaumeiser; William S Winship; Willie Reardon; Eamonn R Maher; David R FitzPatrick; Wim Wuyts; Martin Zenker; Nathalie Lamarche-Vane; Richard C Trembath
Journal:  Am J Hum Genet       Date:  2011-05-13       Impact factor: 11.025

6.  A TCTN2 mutation defines a novel Meckel Gruber syndrome locus.

Authors:  Ranad Shaheen; Eissa Faqeih; Mohammed Z Seidahmed; Asma Sunker; Faten Ezzat Alali; Khadijah AlQahtani; Fowzan S Alkuraya
Journal:  Hum Mutat       Date:  2011-05-05       Impact factor: 4.878

7.  Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA.

Authors:  Sofia Edlund; Maréne Landström; Carl-Henrik Heldin; Pontus Aspenström
Journal:  Mol Biol Cell       Date:  2002-03       Impact factor: 4.138

8.  Nemaline myopathy caused by mutations in the muscle alpha-skeletal-actin gene.

Authors:  B Ilkovski; S T Cooper; K Nowak; M M Ryan; N Yang; C Schnell; H J Durling; L G Roddick; I Wilkinson; A J Kornberg; K J Collins; G Wallace; P Gunning; E C Hardeman; N G Laing; K N North
Journal:  Am J Hum Genet       Date:  2001-04-27       Impact factor: 11.025

9.  Combined immunodeficiency associated with DOCK8 mutations.

Authors:  Qian Zhang; Jeremiah C Davis; Ian T Lamborn; Alexandra F Freeman; Huie Jing; Amanda J Favreau; Helen F Matthews; Joie Davis; Maria L Turner; Gulbu Uzel; Steven M Holland; Helen C Su
Journal:  N Engl J Med       Date:  2009-09-23       Impact factor: 91.245

Review 10.  Autozygome decoded.

Authors:  Fowzan S Alkuraya
Journal:  Genet Med       Date:  2010-12       Impact factor: 8.822

View more
  51 in total

1.  Exome sequencing unravels unexpected differential diagnoses in individuals with the tentative diagnosis of Coffin-Siris and Nicolaides-Baraitser syndromes.

Authors:  Nuria C Bramswig; Hermann-Josef Lüdecke; Yasemin Alanay; Beate Albrecht; Alexander Barthelmie; Koray Boduroglu; Diana Braunholz; Almuth Caliebe; Krystyna H Chrzanowska; Johanna Christina Czeschik; Sabine Endele; Elisabeth Graf; Encarna Guillén-Navarro; Pelin Özlem Simsek Kiper; Vanesa López-González; Ilaria Parenti; Jelena Pozojevic; Gulen Eda Utine; Thomas Wieland; Frank J Kaiser; Bernd Wollnik; Tim M Strom; Dagmar Wieczorek
Journal:  Hum Genet       Date:  2015-02-28       Impact factor: 4.132

Review 2.  Rho GTPases in embryonic development.

Authors:  Philippe M Duquette; Nathalie Lamarche-Vane
Journal:  Small GTPases       Date:  2014

3.  DOCK6 inactivation highlights ISGylation as RHO-GTPase balancer.

Authors:  Berati Cerikan; Elmar Schiebel
Journal:  Cell Cycle       Date:  2016-11-10       Impact factor: 4.534

4.  Diffuse angiopathy in Adams-Oliver syndrome associated with truncating DOCK6 mutations.

Authors:  Anna Lehman; Anna-Barbara Stittrich; Gustavo Glusman; Zheyuan Zong; Hong Li; Patrice Eydoux; Christof Senger; Christopher Lyons; Jared C Roach; Millan Patel
Journal:  Am J Med Genet A       Date:  2014-08-04       Impact factor: 2.802

Review 5.  Skin manifestations in CDG.

Authors:  D Rymen; J Jaeken
Journal:  J Inherit Metab Dis       Date:  2014-02-20       Impact factor: 4.982

6.  Impaired O-linked N-acetylglucosaminylation in the endoplasmic reticulum by mutated epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine transferase found in Adams-Oliver syndrome.

Authors:  Mitsutaka Ogawa; Shogo Sawaguchi; Takami Kawai; Daita Nadano; Tsukasa Matsuda; Hirokazu Yagi; Koichi Kato; Koichi Furukawa; Tetsuya Okajima
Journal:  J Biol Chem       Date:  2014-12-08       Impact factor: 5.157

7.  Whole-Exome Sequencing of Adult and Pediatric Cohorts of the Rare Vascular Disorder Systemic Capillary Leak Syndrome.

Authors:  Richard Pierce; Weizhen Ji; Eunice C Chan; Zhihui Xie; Lauren M Long; Mustafa Khokha; Saquib Lakhani; Kirk M Druey
Journal:  Shock       Date:  2019-08       Impact factor: 3.454

8.  POC1A truncation mutation causes a ciliopathy in humans characterized by primordial dwarfism.

Authors:  Ranad Shaheen; Eissa Faqeih; Hanan E Shamseldin; Ramil R Noche; Asma Sunker; Muneera J Alshammari; Tarfa Al-Sheddi; Nouran Adly; Mohammed S Al-Dosari; Sean G Megason; Muneera Al-Husain; Futwan Al-Mohanna; Fowzan S Alkuraya
Journal:  Am J Hum Genet       Date:  2012-07-26       Impact factor: 11.025

9.  X-Linked Candidate Genes for a Ciliopathy-Like Disorder.

Authors:  Ashleigh R Pavey; Thierry Vilboux; Holly E Babcock; Margot Ahronovich; Benjamin D Solomon
Journal:  Mol Syndromol       Date:  2016-03-16

10.  Mutations in EOGT confirm the genetic heterogeneity of autosomal-recessive Adams-Oliver syndrome.

Authors:  Ranad Shaheen; Mona Aglan; Kim Keppler-Noreuil; Eissa Faqeih; Shinu Ansari; Kim Horton; Adel Ashour; Maha S Zaki; Fatema Al-Zahrani; Anna M Cueto-González; Ghada Abdel-Salam; Samia Temtamy; Fowzan S Alkuraya
Journal:  Am J Hum Genet       Date:  2013-03-21       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.